Skip to main
TBPH
TBPH logo

Theravance Biopharma (TBPH) Stock Forecast & Price Target

Theravance Biopharma (TBPH) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 29%
Hold 29%
Sell 6%
Strong Sell 0%

Bulls say

Theravance Biopharma demonstrated a notable revenue increase of 6.8% in the fourth quarter of 2023, reaching $18.8 million, driven by a strong performance in hospital doses, which grew by 49% year-over-year. The company’s commitment to expanding its hospital channel is expected to support further sales growth into 2025, supported by the strong momentum of its FDA-approved product, YUPELRI, which has shown exceptional growth in hospital accounts. Additionally, potential future approvals could enhance revenue through milestone payments and tiered royalties, indicating a promising outlook for the company’s financial performance.

Bears say

Theravance Biopharma Inc. reported a non-GAAP loss per share of $0.05, which was under the company's own estimate as well as the street consensus, indicating weaker financial performance than anticipated. The company also faced a loss on extinguishment of debt, which added financial strain. Additionally, the challenges associated with forecasting revenues following loss of exclusivity (LOE), compounded by the complexities of developing generic versions of their triple-combination therapy, raise concerns about the sustainability of cash flows in the future.

Theravance Biopharma (TBPH) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Theravance Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Theravance Biopharma (TBPH) Forecast

Analysts have given Theravance Biopharma (TBPH) a Buy based on their latest research and market trends.

According to 17 analysts, Theravance Biopharma (TBPH) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Theravance Biopharma (TBPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.